

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC that the shortage for Telmisartan HCTZ 80 mg/12.5 mg Tablet (DIN 02390302) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 22, 2019**.

TELMISARTAN/ HYDROCHLOROTHIAZIDE

80 MG / 12.5 MG TABLET

00002419114	ACH-TELMISARTAN HCTZ	AHI	\$ 0.2098
00002456389	AURO-TELMISARTAN HCTZ	AUR	\$ 0.2098
00002393557	SANDOZ TELMISARTAN HCT	SDZ	\$ 0.2098
00002390302	TELMISARTAN HCTZ	SIV	\$ 0.2098
00002395355	TELMISARTAN/HCTZ	SNS	\$ 0.2098
00002330288	TEVA-TELMISARTAN HCTZ	TEV	\$ 0.2098
00002244344	MICARDIS PLUS	BOE	\$ 1.2474

Alberta Blue Cross has been advised by Aspen Pharmacare Canada Inc. that the shortage for Arixtra 7.5 mg/0.6 ml Injection Syringe (DIN 02258056) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 22, 2019**.

FONDAPARINUX SODIUM

7.5 MG / SYR INJECTION SYRINGE

00002258056	ARIXTRA (0.6 ML SYRINGE)	APC	\$ 17.5000
00002406896	FONDAPARINUX SODIUM (0.6 ML SYRINGE)	DRL	\$ 18.1356

... continued from previous page

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Naratriptan 1 mg Tablet (DIN 02314290) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2019**.

NARATRIPTAN HCL

1 MG TABLET

00002314290	TEVA-NARATRIPTAN	TEV	\$ 11.9041
00002237820	AMERGE	GSK	\$ 14.7667

Alberta Blue Cross has been advised by AA Pharma Inc that the shortage for Lorazepam 2 mg Sublingual Tablet (DIN 02410761) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 29, 2019**.

LORAZEPAM

2 MG SUBLINGUAL TABLET

00002410761	LORAZEPAM	AAP	\$ 0.1711
00002041472	ATIVAN	PFI	\$ 0.2328

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.795 2019/04

